Acadia Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. Its products include ACP-103, which is in Phase III clinical trials for the treatment of Parkinson’s disease psychosis, and in Phase II clinical trials for the treatment of schizophrenia and sleep maintenance insomnia. The company’s products also comprise ACP-104, a Phase II clinical trial product for the treatment of schizophrenia; and AGN-XX and AGN-YY, which are in Phase II clinical trials for the treatment of neuropathic pain in collaboration with Allergan, Inc. In addition,...